World Journal of Cardiology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 9

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8302)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

617

WORD

185

HTML

3559

Tables (1-5)

594

Sum=4955

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

503

Download

952

Sum=1455

Publishing Process of This Article

Item

Count

Browse

619

Download

1274

Sum=1893

Sep 26, 2021 (publication date) through Mar 26, 2026

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Naito R, Kasai T. Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy. World J Cardiol 2021; 13(9): 464-471 [PMID: 34621491 DOI: 10.4330/wjc.v13.i9.464]
URL:	https://www.wjgnet.com/1949-8462/full/v13/i9/464.htm

Number	Citing Articles
1	Mrinal Kanti Guha. SGLT-2 INHIBITORS – AN ANTIDIABETIC WITH CARDIOPROTECTIVE EFFECTS. INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH 2021; : 50 doi: 10.36106/ijsr/7904180
2	Andrew Xanthopoulos, Grigorios Giamouzis, John Skoularigis, Filippos Triposkiadis. Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost?. World Journal of Cardiology 2022; 14(7): 438-445 doi: 10.4330/wjc.v14.i7.438 Abstract(1279) \| Core Tip(900) \| Full Article(HTML)(6853) \| Full Article (PDF)-3660K(457) \| Full Article (Word)-1485K(76) \| Audio-923K(23) \| Peer-Review Report-941K(144) \| Answering Reviewers-176K(160) \| Times Cited (8) \| Total Visits (16837) \| Open
3	Shaimaa M. Hafez, Eman Mohammed Elsaeed, Amal Hussain Mohammed Ali, Eman S. Said, Yara S. Abouelela, Asmaa Abdo Elshiech, Heba Abdelnaser Aboelsoud, Hala Magdy Anwer, Samar H. Elsharkawy, Marwa A. Ibrahim, Hamdy Rizk, Hoda A. Abd-Ellatieff. Empagliflozin and platelet-rich plasma improve stanozolol induced cardiotoxicity by reducing NF-κB/P65, IL-1B and apoptosis. BMC Pharmacology and Toxicology 2026; 27(1) doi: 10.1186/s40360-026-01086-3
4	Ryo Naito, Takatoshi Kasai. One Step Towards Tailor-Made Medicine for Patients with Heart Failure. European Journal of Heart Failure 2023; 25(8): 1254 doi: 10.1002/ejhf.2941